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BACKGROUND: Primary radiotherapy (RT) is a mainstay of treatment for laryngeal squamous cell carcinoma (LSCC). Although the cure
rates for early (T1) vocal cord tumours are high, RT proves ineffective in up to a third of T3 carcinomas. Moreover, RT is associated
with debilitating early- and late-treatment-related toxicity, thus finding means to de-escalate therapy, while retaining/augmenting
therapeutic effectiveness, is highly desirable. p53 is a key mediator of radiation responses; we therefore investigated whether
Nutlin-3, a small-molecule inhibitor of MDM2 (mouse double minute 2; an essential negative regulator of p53), might radiosensitise
LSCC cells.
METHODS: We performed clonogenic assays to measure radiosensitivity in a panel of LSCC cell lines (for which we determined p53
mutational status) in the presence and absence of Nutlin-3.
RESULTS: LSCC cells harbouring wild-type p53 were significantly radiosensitised by Nutlin-3 (Po0.0001; log-rank scale), and displayed
increased cell cycle arrest and significantly increased senescence (Po0.001) in the absence of increased apoptosis; thus, our data
suggest that senescence may mediate this increased radiosensitivity.
CONCLUSION: This is the first study showing Nutlin-3 as an effective radiosensitiser in LSCC cells that retain wild-type p53. The clinical
application of Nutlin-3 might improve local recurrence rates or allow treatment de-escalation in these patients.
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Squamous cell carcinoma of the head and neck (SCCHN) is the
sixth commonest cancer in the world, with an estimated
global incidence of 500000 cases per year (Parkin et al, 2005).
Despite recent advances in treatment strategies, the overall 5-year
survival has not significantly improved over the last 20 years
(http://www.cancerresearchuk.org.uk/cancerstats/index.htm) and
currently stands at B60%. Radiotherapy (RT) remains one of
the cornerstones of treatment for SCCHN, and a major objective in
current research has been, and continues to be, to identify agents
that may sensitise tumours to the effects of radiation, not only to
improve efficacy but also to reduce treatment-associated toxicity.
In the present study, we have examined the effects of one such
agent, Nutlin-3.
The most commonly mutated gene in human cancers is the
tumour suppressor gene p53 (TP53) and mutation of TP53 has
been implicated in B50% of all SCCHNs (Saunders et al, 1999;
Poeta et al, 2007). The TP53 gene encodes the protein p53, a
transcriptional regulator that is activated in response to a wide
range of cellular stresses, resulting either in a delay in cell cycle
progression (providing an opportunity for DNA damage repair)
and in some cases in senescence or in the initiation of
programmed cell death (apoptosis) (for review see Vousden,
2006). As the p53 gene is pivotal in activating cellular responses to
a wide range of stresses including DNA damage, it is not surprising
that the ability of tumour cells to respond to chemo- and
radiotherapy depends, at least in part, on the p53 pathway
(Temam et al, 2000; Gudkov and Komarova, 2003; Soussi, 2003).
The potential lethality resulting from activation of p53 requires
reliable negative regulation, and two related genes, MDM2 (mouse
double minute 2) and MDMX, have been proven to have critical
roles in this process (Marine and Jochemsen, 2004; Toledo and
Wahl, 2006). Of these two genes, the best understood is MDM2
(Iwakuma and Lozano, 2003). MDM2 negatively regulates p53, and
recent studies have shown that the ability of MDM2 to act as a
ubiquitin ligase targeting p53 for degradation by the proteasomes
is essential for this (Itahana et al, 2007b). MDM2 is also a trans-
criptional target of p53, and thus an autoregulatory feedback loop
regulates p53/MDM2 homoeostasis (Wu et al, 1993). In response to
cellular stress such as DNA damage, post-translational modifi-
cations of p53 (and, although less well understood, of MDM2)
prevent their interaction, resulting in increased levels of p53, which
then activates target gene expression (Balint and Vousden, 2001;
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sMeek and Knippschild, 2003; Bode and Dong, 2004). In normal
cells, this ultimately leads to increased MDM2 expression, and
in the absence of continued/further stress signaling, this returns
p53 to pre-stress levels. MDM2 binds to p53 through
a hydrophobic pocket on the MDM2 surface, and this provides a
potential drug target (Kussie et al, 1996). Successful drug targeting
of this site would present new opportunities for developing
therapeutic regimens for cancers that retain wild-type p53. One
drug that targets the p53-binding pocket of MDM2 and thus acts to
inhibit p53/MDM2 interaction is Nutlin-3, developed by Roche
(Nutley, NJ, USA) (Vassilev, 2004; Vassilev et al, 2004; Carvajal
et al, 2005). Nutlin-3 is a small-molecule inhibitor that binds
preferentially to the p53-binding pocket of MDM2, leading to
stabilisation of p53 and activation of the p53 pathway. This has
been shown to be effective in several models of cancer that harbour
wild-type p53, including prostate, leukaemia and myeloma
(Kojima et al, 2005; Stuhmer and Bargou, 2006; Lehmann et al,
2007). Moreover, Nutlin-3 has been shown to be an effective
radiosensitiser in some forms of cancer (Cao et al, 2006; Lehmann
et al, 2007).
The purpose of our study was to determine the effect of Nutlin-3
treatment on SCCHN cells. We focused on laryngeal squamous
cell carcinomas (LSCC) for two reasons. First, cancers of the
larynx are one of the most common sub-type of SCCHNs and
second, to avoid potentially confounding effects resulting from
the considerable biological heterogeneity manifested by SCCHNs
from different anatomical sub-sites, which result in differences in
their pathogenesis and prognosis (Berrino, 1998). In addition, as
RT is a major treatment modality for SCCHNs including LSCC,
we have examined whether Nutlin-3 alters radiosensitivity in
LSCC cells. Our aim was to determine whether the use of a small-
molecule inhibitor of MDM2 might provide a means to augment
the treatment of patients with LSCC/SCCHNs, which would be
based on the knowledge of the patient’s p53 status.
METHODS
Reagents
Mouse monoclonal antibodies against human MDM2 (Ab-1), p53
(Ab-6) and p21 (CDKN1A; Ab-1), were all purchased from
Calbiochem (San Diego, CA, USA). The anti-actin (C-2, used as a
total protein loading control) and the anti-p21 (anti-CDKN1A; F-5)
antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Secondary antibodies were anti-mouse HRP, used
at a dilution of 1:2500 (from GE Healthcare, Little Chalfont, UK).
Cell culture
The UM-SCC cell lines were kindly provided by Professor TE
Carey, University of Michigan, USA (Krause et al, 1981; Carey et al,
1983; Frank et al, 1997). These were derived from patients known
to have LSCC (Table 1). Cells lines were grown in Dulbecco’s
modified Eagle’s media (Sigma, Poole, UK) containing 10% fetal
bovine serum, 1% non-essential amino acids, 1% L-glutamine and
1% penicillin–streptomycin, and were incubated at 371Ci na
humidified atmosphere containing 5% CO2.
TP53 gene mutation analysis
The PCR amplified exons 1–10 of the TP53 gene were sequenced.
The PCR primers were designed to include the entire exon-coding
sequence and exon–intron junctions (Primer3 v0.4.0, Rozen and
Skaletsky, 2000) as summarised in Supplementary Data Table 1.
Genomic DNA (50ng) was amplified in triplicate using HotStarTaq
plus DNA polymerase (Qiagen, Crawley, UK), using an initial 951C
for 5min, followed by 35 cycles of 941C for 30s, 61–651C for 30s,
721C for 60s and a 10min at 721C final extension. Residual primers
and dNTPs were removed by exonuclease I and shrimp alkaline
phosphatase (ExoSAP-IT, GE Healthcare, Little Chalfont, UK).
DNA sequencing was performed using DYEnamic ET Dye
Terminators (GE Healthcare). Sequencing reactions were purified
by gel filtration (genClean 96-Well Dye Terminator Removal Kit;
Genetix Limited, New Milton, UK) before analysis by capillary
electrophoresis (Megabace 1000 DNA sequencing system;
GE Healthcare). The resulting sequence was compared with the
Homo sapiens chromosome 17 contig NT_010718.15, positions
7189581-7169068bp, using Sequencher v 4.7 software (Gene Codes
Corporation, Ann Arbor, MI, USA). Sequence variants were scored
if they were present in both the sense and the antisense strand of
all three replicates.
Drug sensitivity evaluation
A total of 2 10
5 cells were seeded into each well of a six-well plate
and incubated for 24h. After incubation, Nutlin-3 (a racemic mix
of the active enantiomer, Nutlin-3a, and an inactive enantiomer,
Table 1 Characteristics and TP53 status of laryngeal squamous cell lines used in this study
Cell line TNM
a Grade
a Stage
Type of
lesion
Primary
location
Authenti-
cation
Primary
reference
Reported p53
status
b
p53 Status
(this study)
Nutlin
response
p53
Mutation
effect
UM-SCC-5 T2N1M0 PD III Primary Supraglottis D Krause et al (1981) Het: 157 gtc-ttc
(transversion) V-F
Het: 157 gtc-ttc
(transversion) V-F
RD N
UM-SCC-10A T3N0M0 M-WD III Primary True vocal
cord
D Krause et al (1981) Het: 245 ggc-tgc
(transversion) G-C
Het: 245 ggc-tgc
(transversion) G-C
RD N
UM-SCC-11B T2N2aM0 IV Primary Larynx Carey et al (1983) Mut: 242 tgc-tcc
(transversion) C-S
Mut: 242 tgc-tcc
(transversion) C-S
RT A  ve
(RGC)
UM-SCC-12 T2N1M0 MWD III Recurrence Larynx Carey et al (1983) Het: 104 cag-tag
(termination)
Q-stop
Mut: 104 cag-tag
(termination)
Q-stop
RT A  ve
(RGC)
UM-SCC-17A T1N0M0 MWD I Primary Supraglottis D Carey et al (1983) Wild type Wild type
c S
UM-SCC-17AS T1N0M0 MWD Primary Supraglottis D Carey et al (1983) Wild type Wild type
c S
UM-SCC-81B T2N0M0 MWD II Primary Larynx D Frank et al (1997) Mut: 193 cat-cgt
(transition) H-R
Mut: 193 cat-cgt
(transition) H-R
RD N ?
Abbreviations: DN¼dominant negative; DN?¼questionable dominant negative; Het¼heterozygous mutation, wild-type sequence is also present; mut¼no wild-type sequence
detected – loss of heterozygosity (LOH); M-WD¼moderately to well differentiated; MWD¼moderately well differentiated; PD¼poorly differentiated; R¼resistant; S¼sensitive;
TA ve¼compromised transcriptional activation function (IARC database); TNM¼Tumour node metastasis; WD¼well differentiated.
aTNM classification and staging is
according to the American Joint Committee on cancer of the larynx.
bD indicates that the tumor cell lines were originally compared with microsatellite polymorphisms from
normal tissue or cells from the same individual, as described in Frank et al (1997).
c17A and 17AS are morphologically distinct and 17A grows more slowly.
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sNutlin-3b, obtained from Sigma) was dissolved in DMSO and
diluted in complete media before adding to cells, which were then
incubated as required. Cells were harvested by trypsinisation and
then counted in triplicate by counting three independent samples
using a Beckman Coulter Counter (Beckman Coulter (UK) Ltd.,
High Wycombe, UK (total cell number was counted not including
any detached cells) or using an MTT assay, as indicated.
Clonogenic assays
Cells harvested and counted as above were pre-incubated for
at least 30min with either Nutlin-3 or DMSO. A defined number
of cells, as described in the legend to Figure 4 (determined
empirically for each cell line), were irradiated with 0, 2, 4 or
6Gy at room temperature using a
137Cs source delivering
B6.25Gymin
 1 of g-radiation. After irradiation, cells were
seeded in triplicate into six-well plates and incubated for a period
of 2–3 weeks to permit colony growth for counting (a colony was
defined as a focus of X50 cells, that is, more than five cell
doublings). Plates were then washed with PBS and fixed and
stained with a mixture of 6% (v/v) gluteraldehyde and 0.5% (w/v)
crystal violet for at least 30min. Plates were again washed and then
left to air dry at room temperature overnight before counting
colonies under a light microscope. Plating efficiencies were
calculated and the survival data was fitted to the equation
S(D)/S(0)¼exp ( (aDþbD
2)) to obtain survival parameters
(Dale, 1985).
Western blot analysis
Cells were typically seeded into 25cm
2 flasks and incubated
overnight. The following day, cells were either treated with
Nutlin-3, DMSO or left untreated. After incubation for a further
48h, cells were harvested and proteins extracted as described
previously (Brady et al, 2005). Typically, 50mg samples of total
protein were separated by SDS–PAGE and transferred to Hybond
ECL nitrocellulose membrane (GE Healthcare). Western blotting
was performed as we have described previously (Brady et al, 2005)
and signals were detected using Western Lightning chemilumines-
cence reagent (PerkinElmer, Cambridge, UK) and recorded and
quantitated using a Kodak IS4000MM (Carestream Molecular
Imaging, Woodbridge, CT, USA).
Cell cycle and apoptosis assays
The DNA content and cell cycle distribution of cell populations
was determined by flow cytometry. Cells were seeded as described
above, and the next day drug or vehicle controls were added as
required and cells were then cultured for 48h. For some samples,
after 30min pre-incubation with either Nutlin-3 or DMSO, cells
were exposed to 6Gy irradiation and then incubated as above for
48h. For DNA content analysis, cells were harvested and fixed in
70% ethanol before staining with 25mgml
 1 propidium iodide in a
solution supplemented with 1mgml
 1 RNase (Sigma) in PBS
(pH 7.8) and then analysed on a FACSCalibur instrument
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Figure 1 Nutlin-3 inhibits the proliferation of p53 wild-type laryngeal squamous cell carcinoma cells. Growth curves obtained for laryngeal squamous cell
carcinoma cells in the presence and absence of Nutlin-3. A total of 1–2 10
5 cells, depending on the cell line adherence and growth characteristics, were
seeded in six-well plates and allowed to attach for 24h after which they were either left untreated, treated with DMSO (the vehicle for Nutlin-3) or treated
with Nutlin-3 at a range of concentrations, as indicated. Cells were harvested 24 and 48h later and counted in a Beckman Coulter Counter. Error bars
represent the s.e.m. from three independent wells. The results shown are from a typical experiment repeated on at least three occasions.
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s(BD Biosciences, Oxford, UK). For apoptosis determination, cells
were treated as above except that unfixed cells were analysed for
Annexin-V surface expression using an Annexin-V-FLUOS stain-
ing kit (Roche) and then stained with propidium iodide according
to the manufacturer’s instructions.
Senescence measurement
A senescence-associated b-galactosidase (SA-b-gal) assay (Dimri
et al, 1995) was used to indicate the level of senescence in each cell
line treated with Nutlin-3 or DMSO, with and without exposure to
6Gy of irradiation. A total of 2 10
5 cells were seeded into each well
of a six-well plate, incubated for 24h to permit attachment and then
treated with either Nutlin-3 or an equal volume of DMSO for 48h.
Some samples were pre-incubated for 30min with either Nutlin-3 or
DMSO and then irradiated with 6Gy of g-radiation before seeding.
After culturing for the indicated time, cells were washed with PBS
and fixed for 15min in a solution of 2% formaldehyde and 0.2%
gluteraldehyde at room temperature. Cells were then washed twice
in PBS and then incubated overnight at 371C in 1mgml
 1 X-gal
(5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside), 37mM citric
acid/127mM di-sodium hydrogen phosphate (pH 6.0), 150mM NaCl,
2m M MgCl2,5 m M potassium ferrocyanide and 5mM potassium
ferricyanide. The next day, cells were examined under a microscope
for the development of staining indicative of senescence. Percentages
of SA-b-gal-positive cells were determined by scoring 300 cells from
each of three independent wells.
RESULTS
Table 1 lists the cell lines used in this study, which were all derived
from patients with primary squamous cell carcinoma of the larynx
with the exception of UM-SCC-12 (recurrence after primary
surgery). The confirmed TP53 status of each cell line, analysed
using DNA sequence analysis of the entire coding sequence
including intron/exon boundaries, is also included in Table 1. In
this group of seven cell lines, two are wild-type (UM-SCC-17A and
UM-SCC-17AS), two harbour heterozygous mutations (UM-SCC-5
and UM-SCC-10A), two (UM-SCC-11B and UM-SCC-81B) harbour
only mutant p53 (with loss of heterozygosity (LOH)) and one
harbours a truncation mutation with LOH (p53 null; UM-SCC-12).
The sensitivity of each cell line to varying concentrations of
Nutlin-3 in the range from 0.2 to 5mM (range selected on the basis
of both preliminary scoping experiments indicating that 10mM had
no additional effect, which accords with other studies that have
found that maximal effects of Nutlin are achieved in vitro at p5mM
(Vassilev et al, 2004; Tovar et al, 2006)) is depicted in Figure 1 and
summarised in Table 1. Similar results were obtained using an
MTT assay to monitor cells (see Supplementary Data Figure 1).
Dose-dependent sensitivity to Nutlin-3 is displayed by both wild-
type lines UM-SCC-17A and UM-SCC-17AS, whereas all of the
mutant lines display essentially identical growth in the presence
and absence of Nutlin-3. To investigate the effects of Nutlin-3
further, the steady-state protein levels of p53, MDM2 and p21
(CDKN1a) were measured by western blot analysis after 48h of
treatment with varying concentrations of the drug, as shown in
Figure 2. As expected, p53 could not be detected in UM-SCC-12
cells, which possess only a truncated form of p53 (Q104Stop).
UM-SCC-5 displayed two distinct bands of p53, suggestive of
polymorphism. This was confirmed by sequencing, which showed
that at codon72, this line harbours alleles encoding both proline
and arginine (data not shown). As expected, only the two p53 wild-
type cell lines (UM-SCC-17AS and UM-SCC-17A) displayed
increased expression of p53, MDM2 and p21 after treatment with
MDM2
p53
UM-SCC-10A (het) UM-SCC-11B (mut)
p21
β-Actin
MDM2
p53
p21
β-Actin
UM-SCC-17A (wt) UM-SCC-17AS (wt) UM-SCC-81B (mut)
Untreated
DMSO
0.5 M nutlin-3
5 M nutlin-3
Untreated
DMSO
0.5 M nutlin-3
5 M nutlin-3
Untreated
DMSO
0.5 M nutlin-3
5 M nutlin-3
Untreated
DMSO
0.5 M nutlin-3
5 M nutlin-3
Untreated
DMSO
0.5 M nutlin-3
5 M nutlin-3
Untreated
DMSO
0.5 M nutlin-3
5 M nutlin-3
Untreated
DMSO
0.5 M nutlin-3
5 M nutlin-3
UM-SCC-5 (het) UM-SCC-12 (null)
Figure 2 Nutlin-3 treatment induces p53 target gene expression in p53 wild-type laryngeal squamous cell carcinoma cells. Western blot analysis of
laryngeal squamous cell carcinoma cells harvested 48h after either no treatment, treatment with DMSO (vehicle control) or treatment with Nutlin-3 at
0.5mM or 5.0mM, as indicated. All lanes were loaded with 50mg of protein. Blots were probed with antibodies for p53, MDM2, p21 and b-actin (protein
loading control) as indicated. Note the absence of any detectable p53 in UM-SCC-12 cells, known to be p53 null from DNA sequence analysis (Q104Stop,
LOH). UM-SCC-5 shows two distinct bands of p53 protein, indicative of a well-documented polymorphism in codon 72, which was also confirmed by DNA
sequence analysis (codon 72 is Pro/Arg, data not shown). The results shown are from a typical experiment repeated on at least three occasions.
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sNutlin-3. This accords with studies that have shown that the
sensitivity of cells to Nutlin-3 is due to an increase of intracellular
p53, with a concomitant rise in p21 expression (as well as MDM2)
(Vassilev et al, 2004), although the role of p21 function has
recently been called into question (Kan et al, 2007). Next, we
determined the cell cycle profile of cells treated with Nutlin-3 by
flow cytometry. Figure 3 summarises the results (also see
Supplementary Data Figure 2) from a typical experiment, and
shows that there is a reduction in the S-phase population and a
concomitant increase in the G1 population in the wild-type cells
with increasing doses of Nutlin-3. This is typical of cell cycle arrest,
primarily in G1, and as Figure 2 suggested, this cell cycle arrest is
likely to be caused by a p53-mediated increase in p21 expression in
wild-type cells (Waldman et al, 1995; Vassilev et al, 2004). No such
change is detectable in the cell cycle profile in any of the other cell
lines (we have however noted evidence of a G2/M arrest (reduced
G1 and increased G2/M population) in the p53-mutant line,
UM-SCC-81B, an event that can be both p53 independent
(Bernhard et al, 1995) and p53 dependent-mediated through
14-3-3s; reviewed in Hermeking and Benzinger (2006). It has been
shown previously that cells in G1 are approximately twice as
radiosensitive as cells in S-phase (Pawlik and Keyomarsi, 2004),
and therefore we considered the possibility that the cell cycle arrest
that we observed in wild-type cells might also lead to increased
radiosensitivity. It has been shown previously (Lehmann et al,
2007) that pre-treatment of prostate cancer cells with Nutlin-3
leads to increased radiosensitivity, and therefore we used a
similar experimental regimen to investigate this in LSCC cells.
We performed in vitro clonogenic assays for LSCC cells after short-
term (30min) pre-treatment with high-dose Nutlin-3 (5mM)o r
DMSO (vehicle control) followed by exposure to g-radiation at 0, 2,
4 or 6Gy, as illustrated in Figure 4. Pre-treatment with Nutlin-3
had a significant effect on the p53 wild-type cells, making them
significantly more radiosensitive (comparison of SF2 values;
Po0.0001, log-rank scale). As expected from our earlier data,
Nutlin-3 treatment had no significant effect on any of the other
cells. Perhaps, surprisingly, the survival curves obtained also show
that cells with homozygous/LOH mutations of TP53 are signifi-
cantly (Po0.001) more radiosensitive than those with wild-type,
heterozygous or null mutations, but we have not determined
whether this is a causal relationship.
Having shown that Nutlin-3 pre-treatment of TP53 wild-type
cells results in a significant increase in radiosensitivity, we next set
out to investigate the mechanism underlying this difference.
Induction of p53 is well documented to induce apoptosis (Oren,
2003), and thus one simple explanation for the reduced survival
after exposure to ionising radiation in the presence of Nutlin-3 is
that this leads to increased p53-dependent apoptosis. As shown in
Figure 3, flow cytometry did not detect any increase in the sub-G1
population of cells in response to Nutlin-3 treatment, and thus we
conclude that this is unlikely to provide an explanation for this
effect. Nevertheless, to further investigate this phenomenon, we
used an alternative assay for apoptosis based on Annexin-V detec-
tion of surface-translocated phosphatidylserine (van Engeland
et al, 1998). Figure 5 shows that Nutlin-3 has no detectable
impact on Annexin-V positivity in response to 6Gy of ionising
radiation in any of the cells tested (also see Supplementary Data
Figure 3). Irradiation does induce an increase in Annexin-V
staining, indicative of apoptosis in the p53-mutant (presumed
LOH) and null cells, but this was not affected by pre-treatment
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Figure 3 Nutlin-3 induces cell cycle arrest in p53 wild-type laryngeal squamous cell carcinoma cells. Histograms summarising data obtained by flow
cytometry after propidium iodide staining (PI) of fixed laryngeal squamous cell carcinoma cells (also see Supplementary Data Figure 2). Cells were seeded
and either left untreated (No Tx) or were treated for 48h with DMSO, 0.5mM Nutlin-3 or 5mM Nutlin-3 as indicated. Cells were harvested, fixed in ethanol
and stained with propidium iodide. The results shown are from a typical experiment repeated on at least three occasions.
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swith Nutlin-3. Combining the data from Figures 3 and 5, we
conclude that apoptosis is unlikely to mediate the increase in
radiosensitivity that we have observed in p53 wild-type LSCC cells
pre-treated with Nutlin-3.
One possible explanation for the effect of Nutlin-3 that we have
observed is that, upregulation of p53 might induce cellular
senescence. Senescent cells undergo a number of morphological
changes and one indication of this that has been reported is an
increase in cell size and granularity, which can be detected as
increased forward scatter and side scatter, respectively, by flow
cytometry (Masterson and O’Dea, 2007). We therefore analysed the
same samples shown in Figure 5, and as Figure 6 shows, we
detected in one wild-type line, 17AS, a significant increase
(P¼0.0001) in the forward and side scatter of cells in response
to exposure to 6Gy of ionising radiation in cells pre-treated with
Nutlin-3 (this was not significant in the other wild-type cell line,
17A; P¼0.08). To simplify this analysis, we have scored cells
according to whether they belong to the area defined by the
majority cell population (that is, inside the plot frame denoted as
‘in’) or whether they have become so increased in size and/or
complexity as to lie outside of the plot frame (denoted as ‘out’). It
is striking that in the presence of Nutlin-3, both the p53 wild-type
lines displayed a significant increase in size and/or granularity. We
note that two other cell lines UM-SCC 5 and 12 also display a
significant increase in response to 6Gy of radiation, but this was
not enhanced by the addition of Nutlin-3. Although increasing cell
size and granularity are characteristics of senescent cells, we
wanted to use a more direct and independent assay for senescence
to determine whether these physical changes were accompanied by
other characteristics of senescence. We therefore performed a
SA-b-Gal assay (for review see Itahana et al, 2007a) on cells
exposed to 6Gy of ionising radiation with and without Nutlin-3
pre-treatment. Figure 7 shows that there is a significant increase
(Po0.01) in the percentage of senescent p53 wild-type cells when
these are pre-treated with Nutlin-3. We have also noted a
significant increase in senescence after irradiation in the absence
of Nutlin-3 (Po0.01) in these p53 wild-type cells.
Curiously, the highly radiosensitive cell lines UM-SCC-81B and
11B are the only ones not to display any detectable senescence in
this assay under any of the conditions tested. Nevertheless, as far
as the effect of Nutlin-3 is concerned, our observations support a
possible role for senescence as a mechanism for radiosensitisation
in p53 wild-type LSCC cells that warrants further investigation.
DISCUSSION
Improvements in cancer therapy can derive from the development
of new drugs that target specific changes present in some cancer
cells or indeed in their environment. In the former case, precise
molecular information regarding each patient’s cancer is required
to select appropriate drugs. In the case of LSCC, although RT is
effective in many cases, it is associated with significant treatment-
related toxicity. Our study aims at addressing the therapeutic
response (with potential implications for toxicity issues) by
examining the use of a small molecule to increase radiosensitivity
when targeted to individuals with disease that retains wild-type
p53. We provide evidence that Nutlin-3 can indeed increase the
Nutlin-3 ------O------
——O——
UM-SCC-11B (mut) UM-SCC-5 (het) UM-SCC-10A (het)
02468 02468 02468
0246 8 0 2468 0 2468
0246 8
1
0.1
0.1
1
0.001
0.01
1
0.1
UM-SCC-17AS (wt) UM-SCC-12 (null) UM-SCC-17A (wt)
1
0.1
1
0.1
1
0.1
Surviving
fraction
*P<0.0001 *P<0.0001
UM-SCC-81B (mut)
*Nutlin-3 effect, log
rank scale.
0.1
1
0.001
0.01
0.0001
Dose/Gy
DMSO
Figure 4 Nutlin-3 radiosensitises p53 wild-type laryngeal squamous cell carcinoma cells. Clonogenic assays were performed on laryngeal squamous cell
carcinoma cells exposed to the indicated doses of g-irradiation. Cells were pre-treated with either DMSO or 5mM Nutlin-3 for 30min and then irradiated
with 0, 2, 4 or 6Gy as indicated. Cells were then re-seeded and allowed to form colonies for a period of 2–3 weeks. A colony was defined as containing at
least 50 cells, equivalent to greater than five cell doublings. Colonies were fixed, stained and counted. The number of cells seeded varied according to the
clonogenic characteristics of each cell line: 6400 for UM-SCC-5, 32000 for UM-SCC-10A, 1600 for UM-SCC-11B, 400 for UM-SCC-12, 25000 for
UM-SCC-17AS, 6400 for UM-SCC-17A and 1600 for UM-SCC-81B. The quadratic equation S(D)/S(0)¼exp( (aDþbD
2)) was used to obtain survival
parameters, and all r
2 values were 40.92. Note that cells expressing full-length mutant p53, in the absence of endogenous wild-type p53, were relatively
radiosensitive compared with cells harbouring all other genotypes. The results shown are from a typical experiment repeated on at least three occasions.
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ssensitivity of p53 wild-type LSCC cells to RT and thus propose that
this may provide an opportunity for de-escalating radiation
dosage, without compromising cure rates, as part of a combination
chemo–RT approach for a defined subset of LSCC patients.
Conversely, the enhanced radiosensitivity mediated by Nutlin-3
might improve outcome at currently used radiation doses.
Tp53 is the most frequently mutated gene in human cancer
(Steele and Lane, 2005), and in SCCHN, mutation of p53 and,
moreover, the type of p53 mutation (nonsense or disruptive
missense vs non-disruptive missense) have been shown to be
associated with reduced overall survival for surgically treated
patients (Poeta et al, 2007). Nevertheless, although p53 mutation
occurs frequently in patients with SCCHN (Olivier et al, 2002),
approximately half of these patients retain potentially functional
wild-type p53 (in a recent systematic review, we identified a
mutation frequency for SCCHN of 50.7% in the United Kingdom
(Tandon et al, 2010)). Our results from the present study
suggest that this latter group might benefit from a combination
chemo–RT approach that combines a p53 activator such as
Nutlin-3, with RT, possibly permitting a de-escalation of the
standard RT regimen and/or enhancing the therapeutic effective-
ness of ionising radiation.
To avoid the potentially confounding effect of biological
differences between SCCHN from different anatomical sub-sites,
we have focused on LSCC in this study. However, it appears likely
with respect to p53-targeted therapies that similar results may
be obtained in most of the SCCHN sub-sites. Clearly, it will be
necessary to determine the impact of potentially confounding
factors on Nutlin-3 radiosensitisation. One obvious factor is likely
to be infection with human papilloma virus (HPV). Human
papilloma virus strains that promote cancer do so partly through
inactivating p53, and cancers in some sub-sites, notably the
oropharynx, display a relatively high incidence of HPV infection
that might impact on the effectiveness of drug-induced radio-
sensitisation in this tissue (Hennessey et al, 2009). Nevertheless,
the prospect of a personalised therapy with diminished treatment-
related toxicity seems to be an attractive one for most other
SCCHNs.
Our results in Figure 4 show that Nutlin-3 significantly
(Po0.0001) reduces the ability of p53 wild-type LSCC cells to
proliferate and form foci after exposure to ionising radiation. In
studies of prostate cancer cells, p53 was shown to promote
radiosensitivity and radiation-induced senescence (Lehmann et al,
2007). On the one hand, this clearly accords with the increased
sensitivity and senescence that we have observed in LSCC cells
harbouring wild-type p53 after treatment with Nutlin-3.
Re-introduction of wild-type p53 in prostatic cancer cells has
been shown to render them more sensitive to radiation, and also
increases cellular senescence (Lehmann et al, 2007). These authors
concluded that premature senescence, and not apoptosis, was the
principal mode of death, which lead to failure of prostate cancer
cells to proliferate after exposure to ionising radiation. From our
data it seems that LSCC cells possess a similar pathway with
similar consequences. On the other hand, we have observed that
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Figure 5 Analysis of apoptosis in laryngeal squamous cell carcinoma cells treated with ionising radiation and/or Nutlin-3. Summary of flow cytometric
analysis of LSCC cells after either irradiation with 6Gy or mock treatment. As indicated, cells were pre-treated for 30min with either DMSO or 5mM
Nutlin-3. After treatment, cells were re-seeded for 48h before harvesting. Cells were then incubated with Annexin-V-FITC and propidium iodide to
measure apoptosis and membrane integrity respectively. The log/log plot were divided into four quadrants as shown in Supplementary Data Figure 3, and
the percentage of cells in each quadrant is presented in the histograms. Cells in the lower right quadrant stained with Annexin-V (AVþ/PI ) are indicative
of cells undergoing apoptosis and cells that have died are expected in the upper right quadrant staining for both Annexin-V and propidium iodide
(AVþ/PIþ). Healthy/intact cells are negative for Annexin-V and propidium iodide (AV /PI ). The results shown are from a typical experiment repeated
on at least three occasions.
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Figure 6 Laryngeal squamous cell carcinoma cells display increased complexity and/or size after exposure to ionising radiation and/or Nutlin-3. Flow
cytometric analysis of the same samples shown in Figure 5. Forward vs side scatter plots were analysed to identify cells displaying unusual complexity and/or
size (increased side scatter and/or forward scatter, respectively). Gates were applied to define the main population of cells and numbers of cells lying outside
the gates were recorded. The data are presented in the table as the percentage of gated cells (denoted as ‘in’) and the percentage of more complex and/or
larger cells lying outside the gates (denoted as ‘out’) shown as the darker bar. Cells lying outside the gates are larger and more granular, a phenotype typical
of senescent cells. The results shown are from a typical experiment repeated on at least three occasions.
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Figure 7 Increasing radiosensitivity in response to nutlin-3 treatment is associated with increased senescence. Senescence-associated b-galactosidase
(SA-b-gal) assay of laryngeal squamous cell carcinoma cells after irradiation at 6Gy after B30min of pre-treatment with DMSO or 5mM Nutlin-3. Cells were
treated and seeded for 48h. A b-galactosidase assay was used at low pH (6.0), which stains senescent cells blue/green. A total of 300 cells were counted
from three independent samples per condition, and the percentage of senescent cells as a fraction of the total was calculated. Error is expressed as the s.e.m.
There is a clear increase in the number of senescent cells with Nutlin-3 treatment in TP53 wild-type cells (UM-SCC-17AS and UM-SCC-17A), and also
a further significant increase in senescence after irradiation, which is statistically significant (Student’s t-test). Cells expressing full-length mutant p53 with
LOH (UM-SCC-11B and UM-SCC-81B, the most radiosensitive) did not show any detectable senescence under any of the conditions examined. The results
shown are from a typical experiment repeated on at least three occasions.
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displayed no capacity for senescence under any of the conditions
tested (as illustrated in Figures 4 and 7). This result seems to differ
from the results obtained for prostate cancer cells and from our
results using Nutlin-3. Such differences may be due to tissue-
specific characteristics of prostatic and laryngeal cancer cells, but
this observation requires further investigation to determine
whether or not this reflects a causal association in LSCC cells.
That these lines also exhibit p53 LOH calls for further functional
analysis, but these issues lie outside the scope of this study. There
is one additional observation that we have made that also relates to
LOH. Not only does retention of one wild-type copy in the
presence of a mutant p53 allele (heterozygous mutation) not
render cells sensitive to the growth inhibitory effects of Nutlin-3
(Figure 1) but it also does not render the cells more radiosensitive
(Figure 4). This contrasts with the ability of cells to undergo
senescence, a property displayed by all cells in our study except
those that exhibit p53 LOH (Figure 7). Whether this is due to
p53-independent senescence induction or reflects a separation
between p53 dominant-negative effects on two different pheno-
types is unclear. Nevertheless, our data suggest that examination of
these phenotypes may provide an experimental system to
investigate such questions.
In this study, we have observed that increased radiosensitivity
is linked with increased senescence. Senescence is usually defined
as an irreversible process in which cell growth is arrested.
Phenotypically, this is characterised in some cells by an increase
in cytoplasmic volume and an accumulation of lysosomes, leading
to increased granularity and upregulation of b-galactosidase
expression (Dimri et al, 1995). The p53 gene has been shown to
be capable of promoting a senescent phenotype in cells, but it
remains unclear whether such p53-induced senescence is truly
irreversible or rather represents a protracted, but ultimately
reversible state (Efeyan et al, 2007; Ruiz et al, 2008). In one recent
study, p53 was shown to be necessary for initiation of senescence
in the presence of activated Ras in mouse embryo fibroblasts
(MEFs) (Ruiz et al, 2008). However, it seems that p53 activity
becomes downregulated in senescent cells and may not be required
for maintenance of senescence. Perhaps of greater importance
here, it was also found that maintaining growth arrest for long
periods in MEFs did not result in a senescent phenotype in cells
lacking an activated Ras oncogene. Oncogene activation is a sine
qua non of cancer, and thus the LSCC cells that we have examined
will certainly express at least one and likely several aberrant
oncogenes, although as is typical of SCCHN (Ha and Califano,
2002), none of these cell lines harbour mutations in KRAS (our
unpublished data). It seems likely therefore that the ‘senescence’
that we have detected in LSCC cells is not simply prolonged growth
arrest, but is in fact irreversible genuine senescence.
In conclusion, our study shows that the use of p53-activating
drugs, such as Nutlin-3, can provide an effective means of
radiosensitisation in LSCC cells and likely in the broader context
of SCCHN of known p53 status (specifically those with wild-type
p53). Such an approach offers the prospect of a personalised
combined chemo–RT intervention with reduced treatment-
associated toxicity and/or improved outcome that could benefit
approximately half of all patients with LSCC who are currently
treated with RT.
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